A thiazide test for the diagnosis of renal tubular hypokalemic disorders.
Giacomo Colussi, Alberto Bettinelli, Silvana Tedeschi...
https://pubmed.ncbi.nlm.nih.gov/17699451Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
Healthy Volunteers
ID06841692
Diuretic Testing in Chronic Kidney Disease
Led by Erasmus Medical Center · Updated on 2025-08-07
86
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
E
Erasmus Medical Center
Lead Sponsor
E
European Research Council
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating how diuretic testing can predict the progression of chronic kidney disease (CKD). The study focuses on whether poorer results from this test indicate faster worsening of CKD. It also compares the test results between patients with CKD and healthy individuals to understand differences in kidney function. Participants are randomly assigned to one of two groups: one group receives diuretics (hydrochlorothiazide and bumetanide) to stimulate kidney tubular function, while the other group does not receive diuretics. Blood and urine samples are collected after administration to assess kidney response. This interventional study involves a test day where diuretics are given and monitoring occurs. During the study, participants will undergo diuretic testing with blood and urine collections to evaluate kidney function. Researchers will monitor the progression of CKD over three years as the primary outcome. Safety and adherence will be observed, and participants' health will be assessed throughout the study period. The total involvement includes initial testing and long-term follow-up to measure disease progression.
CONDITIONS
Brief Title
Diuretic Testing in Chronic Kidney Disease
Who Can Participate
Age: 18Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- For CKD participants: Chronic kidney disease stage G3 with creatinine-based eGFR between 30-59 mL/min/1.73m2 at last outpatient visit
- For healthy participants: eGFR within expected range for age, considering normal age-related decline starting from age 40
You will not qualify if you...
- Known intolerance or allergy to hydrochlorothiazide or bumetanide diuretics
- Current systemic chemotherapy for cancer
- Kidney transplant recipient
- Use of calcineurin-inhibitors
- Life expectancy less than 12 months
- Current immunosuppressive treatment for glomerulonephritis
- Unable to follow instructions or deemed unfit for study adherence
- Low or high potassium levels (K+ < 3.0 mmol/L or > 5.5 mmol/L) at inclusion
- Low or high sodium levels (Na+ < 130 mmol/L or > 150 mmol/L) at inclusion
- Inherited tubulopathy causing CKD
- Autosomal dominant polycystic kidney disease or tubulointerstitial kidney disease causing CKD
- Severe heart failure (NYHA class III or IV)
- Therapy-resistant hypertension (systolic blood pressure > 180 mmHg at inclusion)
- Current treatment with inhibitors of organic anion transporters (e.g., probenecid, pravastatin, cimetidine, cephalosporins, acetazolamide)
- Active hepatitis at last outpatient visit
- Advanced liver cirrhosis (Child-Pugh B or C)
- Active drug or alcohol abuse
- Unable to tolerate a 28-day washout of drugs interfering with diuretic testing
- Women who are pregnant, breastfeeding, or planning pregnancy before the test day
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - 1 day
Participants undergo diuretic testing with administration of hydrochlorothiazide and bumetanide to stimulate and assess kidney tubular function.
1 visit (in-person) on the test day
Long-term Monitoring
Duration - 3 years
Participants are monitored for progression of chronic kidney disease over time.
Periodic visits as per study protocol
Trial Site Locations
Total: 1 location
1
Erasmus MC
Rotterdam, South Holland, Netherlands, 3015GD
Actively Recruiting
Loading map...
Research Team
S
Sebastian B Beckmann, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Development and standardization of a furosemide stress test to predict the severity of acute kidney injury.
Lakhmir S Chawla, Danielle L Davison, Ermira Brasha-Mitchell...
https://pubmed.ncbi.nlm.nih.gov/24053972Tubular stress test detects subclinical reduction in renal functioning mass.
B Rodríguez-Iturbe, J Herrera, C Marín...
https://pubmed.ncbi.nlm.nih.gov/11231365